Get the Stockscreener App
12.51
0.00%
0.00
After Hours:
12.51
Xencor Inc stock is traded at $12.51, with a volume of 978.35K.
It is up +0.00% in the last 24 hours and up +4.25% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$12.51
Open:
$12.65
24h Volume:
978.35K
Relative Volume:
1.26
Market Cap:
$917.47M
Revenue:
$125.58M
Net Income/Loss:
$-92.14M
P/E Ratio:
-10.07
EPS:
-1.2424
Net Cash Flow:
$-138.27M
1W Performance:
+2.12%
1M Performance:
+4.25%
6M Performance:
-11.28%
1Y Performance:
+31.13%
1-Day Range:
$12.25
$12.82
1-Week Range:
$12.04
$13.30
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.51 | 917.47M | 125.58M | -92.14M | -138.27M | -1.2424 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor (NASDAQ:XNCR) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Ideas Watch: Is Xencor Inc impacted by rising rates2026 Earnings Surprises & Weekly Top Stock Performers List - baoquankhu1.vn
Xencor CFO Cornelissen sells $42990 in stock By Investing.com - Investing.com India
Xencor CFO Cornelissen sells $42990 in stock - Investing.com
Xencor (XNCR) CFO sells 3,499 shares to cover tax on vested RSUs - Stock Titan
Short Covering: What is the target price for Xencor Inc stockPortfolio Value Report & Short-Term High Return Ideas - baoquankhu1.vn
How (XNCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Gap Down: Will Xencor Inc stock hit new highs in YEAR2026 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Closing: Can Xencor Inc expand its profit marginsMarket Weekly Review & Stepwise Trade Execution Plans - baoquankhu1.vn
Portfolio Recap: Is Xencor Inc stock showing strong momentumAnalyst Upgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Quarterly Recap: Is Xencor Inc stock showing strong momentumWeekly Market Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
[144] Xencor Inc SEC Filing - Stock Titan
Portfolio Shifts: Should value investors consider Xencor Inc2026 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn
Xencor, Inc. (XNCR) Stock forecasts - Yahoo Finance UK
Aug Update: What is the long term forecast for Xencor Inc stock2026 Top Gainers & Community Shared Stock Ideas - baoquankhu1.vn
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Fed Meeting: Is Xencor Inc a top pick in the sector2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Gainers Report: Is Xencor Inc stock showing strong momentumStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Buy Signal: Can Xencor Inc expand its profit marginsPortfolio Value Summary & Short-Term Trading Alerts - baoquankhu1.vn
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com
Trading Systems Reacting to (XNCR) Volatility - Stock Traders Daily
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor SVP Eckert sells $17,747 in shares - Investing.com
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving AverageWhat's Next? - MarketBeat
Aug Weekly: Can Xencor Inc expand its profit marginsRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Xencor falls as royalty dispute with Astra leads to guidance cut - MSN
RA Capital, insiders report shared 6.5% stake in Xencor (NASDAQ: XNCR) - Stock Titan
Big Money Moves: What is the long term forecast for Xencor Inc stock2026 Review & Breakout Confirmation Trade Signals - baoquankhu1.vn
Pharma News: What is the target price for Xencor Inc stock2026 Geopolitical Influence & Reliable Intraday Trade Plans - baoquankhu1.vn
Portfolio Recap: What is the long term forecast for Xencor Inc stockMarket Performance Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Investment Recap: Should you buy the dip on Xencor Inc2026 Momentum Check & Safe Entry Trade Reports - baoquankhu1.vn
Value Recap: Can Xencor Inc disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Vanguard (XNCR) reports 0 shares after internal realignment amendment - Stock Titan
Aug Levels: Is Xencor Inc stock showing strong momentumMarket Performance Report & Verified Technical Signals - baoquankhu1.vn
Buyout Rumor: Is Xencor Inc a top pick in the sectorMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Earnings Beat: Is Xencor Inc stock a good pick for beginnersWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Aug Sentiment: Should value investors consider Xencor Inc2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Shares Gap DownTime to Sell? - marketbeat.com
Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving Average – Here’s What Happened - Defense World
JPMorgan Chase & Co. Reiterates Neutral Rating for Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock downgraded to neutral at JPMorgan on execution concerns By Investing.com - Investing.com Australia
JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18 - MarketScreener
Xencor stock downgraded to neutral at JPMorgan on execution concerns - Investing.com
Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving AverageHere's What Happened - MarketBeat
How Xencor Inc. (XNCR) Affects Rotational Strategy Timing - Stock Traders Daily
XNCR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analyst Upgrade: What is the Moat Score of Xencor Inc2026 Selloffs & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Analyst Calls: What hedge funds are buying Xencor IncLong Setup & Daily Price Action Insights - baoquankhu1.vn
Macro Review: Will Xencor Inc stock hit new highs in YEAR2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):